BIOATLA, INC. Revenue
BIOATLA, INC. (BCAB) reported Revenue of $0 for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-07.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2023-11-07
- BIOATLA, INC. revenues for the quarter ending 2023-09-30 was $0.00.
- BIOATLA, INC. revenues for the quarter ending 2023-06-30 was $0.00.
- BIOATLA, INC. revenues for the quarter ending 2023-03-31 was $0.00.
- BIOATLA, INC. revenues for the quarter ending 2022-09-30 was $0.00.
- BIOATLA, INC. revenues for fiscal 2021 was $300.00K.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 10-Q · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-01 | $0.00 10-Q · filed 2023-08-01 | ||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 | |||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | $0.00 derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-01 | $0.00 10-Q · filed 2023-08-01 | $0.00 derived: sum of 3 quarters · filed 2023-08-01 | $0.00 derived: sum of 4 quarters · filed 2023-08-01 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | $0.00 derived: sum of 2 quarters · filed 2023-05-11 | $0.00 derived: sum of 3 quarters · filed 2023-05-11 | $300.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $0.00 derived: sum of 2 quarters · filed 2023-03-23 | $300.00K derived: sum of 3 quarters · filed 2023-03-23 | $300.00K 10-K · filed 2023-03-23 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $300.00K derived: sum of 2 quarters · filed 2022-11-04 | $300.00K 10-Q · filed 2022-11-04 | |
| 2021-06-30 | $300.00K 10-Q · filed 2022-08-09 | $300.00K 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |